#Paris #France #Opella #Mucosolvan #Bisolvon

New Study from Opella on Cough Treatment Success

A recent study by Opella, the company known for its effective cough treatments Mucosolvan and Bisolvon, has led to compelling insights about how cough management should extend beyond mere symptom relief. This new research indicates that the overall well-being of patients should be a pivotal measure in gauging the effectiveness of cough treatments, especially as many consumers are the ones making choices in pharmacies.

Key Findings of the Study

The results of the study highlight essential findings that can guide pharmacists in their recommendations to patients.

1. Immediate Relief from First Dose

Patients reported significant relief soon after beginning treatment. Observations indicated improvements in daily activities from the very first day of treatment, allowing them to reclaim control over their day-to-day lives swiftly.

2. Enhanced Social Engagement

Within 72 hours, patients exhibited notable improvements in their ability to engage socially, indicating that effective cough treatment allows individuals to participate comfortably in conversations and social activities. This aspect is vital as cough can alienate patients from their social environments.

3. Better Sleep Quality

Sleep disturbances due to coughing are a common issue. The study showed impressive results after just 48 hours, with patients experiencing marked improvement in their ability to fall and stay asleep. Difficulty falling asleep decreased by 59%, while struggles with staying asleep and feeling tired also witnessed reductions of 56% and 55%, respectively.

Expert Opinion

Milena Leone, the Global Brand General Manager at Opella, highlighted the critical nature of adequate cough management. According to her, “When a cough disrupts daily routines, effective and timely care is essential. This study provides valuable, real-world evidence that Mucosolvan and Bisolvon goes beyond managing the physical symptom; by delivering fast-acting relief from the first dose, it helps people move past the disruption of cough and resume their daily lives more quickly.”

About the Study

The Opella RWE Cough Study was an observational study conducted in Italy, involving adult patients who used Mucosolvan (Ambroxol) or Bisolvon (Bromhexine) to combat acute chesty cough. Over a seven-day period, the study assessed both treatment effectiveness and the impact on quality of life, utilizing validated instruments such as the Cough Severity Diary (CSD) and the Leicester Cough Questionnaire (LCQ).

The implications of these findings are significant, especially in nations like Germany, where around 58% of consumers actively engage in selecting their cough and cold remedies directly in pharmacies. The results show that for many patients, encountering relief soon after the first dosage is critical in managing their conditions effectively.

In conclusion, Opella's study reminds healthcare professionals and pharmacists about the broader implications of cough treatment, which should encompass not just the immediate relief from symptoms, but also the enhancement of overall patient well-being, thereby facilitating a quicker return to normal life functionalities.